WeVote

Bill

Bill

HB 2295

Relating to newborn screening tests for Duchenne muscular dystrophy.

89th Legislature (2025) Introduced by Giovanni Capriglione and 2 co-sponsors

Texas bill requiring newborn screening for Duchenne muscular dystrophy to enable earlier diagnosis and potential early intervention in affected infants.

Laid on the table subject to call
0
WeVote Research Nonpartisan
Bill Summary · HB 2295

Legislative bill overview

HB 2295 requires Texas to add Duchenne muscular dystrophy (DMD) to the state's newborn screening panel. DMD is a severe, progressive genetic disorder that causes muscle weakness and degeneration, typically appearing in early childhood. Early detection through newborn screening could enable earlier intervention and treatment options.

Why is this important

Duchenne muscular dystrophy is a rare but devastating condition affecting approximately 1 in 3,500 male births. Early identification allows families to access genetic counseling, monitor disease progression, and potentially benefit from emerging therapies that may slow progression if started early. Texas's current newborn screening panel does not include DMD, meaning affected infants are typically diagnosed only after symptoms become apparent, potentially missing critical windows for treatment.

Potential points of contention

  • Cost and infrastructure: Adding new screening tests increases lab capacity requirements and per-test costs; unclear whether savings from early intervention justify these expenses
  • Limited treatment options: While early detection is valuable, available curative treatments remain limited; some argue resources should prioritize conditions with proven interventions
  • Psychological impact: Positive newborn screening results for an incurable progressive disease could cause parental distress, and counseling infrastructure may need expansion

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.